Gemini
Senior Member
- Messages
- 1,176
- Location
- East Coast USA
On May 8, 2017, FDA’s Pharmacy Compounding Advisory Committee will discuss six bulk drug substances nominated for inclusion on the section 503A Bulks List.
One these substances, nicotinamide adenine dinucleotide disodium reduced (NADH), has been nominated for reducing symptoms of fatigue in ME/CFS.
Additional information can be found at the following web link:
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PharmacyCompoundingAdvisoryCommittee/ucm553328.htm
One these substances, nicotinamide adenine dinucleotide disodium reduced (NADH), has been nominated for reducing symptoms of fatigue in ME/CFS.
Additional information can be found at the following web link:
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PharmacyCompoundingAdvisoryCommittee/ucm553328.htm